Literature DB >> 15216450

Non-functioning pituitary adenomas: endocrinological and clinical outcome after transsphenoidal and transcranial surgery.

M Wichers-Rother1, S Hoven, R A Kristof, N Bliesener, B Stoffel-Wagner.   

Abstract

AIM: To study improvement of anterior pituitary function after transsphenoidal and transcranial surgery of non-functioning (NF) pituitary macro- and microadenomas.
METHODS: We retrospectively examined 155 patients with NF adenomas preoperatively and 3 months, 1 year and 2 years postoperatively. 130 patients harboured a macroadenoma, 109 underwent transsphenoidal (group one), 21 transcranial surgery (group two). 25 patients presented a microadenoma (transsphenoidal surgery, group three). Endocrine studies included basal serum levels and dynamic testing of anterior pituitary partial function. Clinical symptoms and hormone replacement therapy were documented.
RESULTS: Preoperatively, in group one, two and three, somatotropic function was impaired in 85, 90 and 80 %, gonadotropic in 61, 57 and 24 %, corticotropic in 31, 38 and 28 %, thyreotropic in 32, 38 and 12 % and lactotropic in 22, 38 and 32 % cases, respectively. Pituitary functions did not improve significantly after transsphenoidal or transcranial surgery. Presurgically, 63, 62 and 0 % patients complained about visual impairments, 60, 48 and 40 % about headache, 53, 24 and 36 % about fatigue and 28, 33 and 20 % about disturbance of cycle or potency. After transsphenoidal surgery, impaired vision, headache and fatigue improved within 3 months; after transcranial surgery, only headache improved. Preoperatively, pituitary malfunctions were treated adequately. Postsurgically, more patients received adrenal and thyroid hormone substitution, less patients received sex hormones than examinations proved necessary.
CONCLUSION: Anterior pituitary function of NF adenoma patients did not improve significantly after transsphenoidal or transcranial surgery. After transsphenoidal surgery, most clinical symptoms normalised within 3 months. In some of the patients, substitution was not optimally adjusted to hormonal impairments.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15216450     DOI: 10.1055/s-2004-820914

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  22 in total

Review 1.  Central hypothyroidism and its role for cardiovascular risk factors in hypopituitary patients.

Authors:  Ulla Feldt-Rasmussen; Marianne Klose
Journal:  Endocrine       Date:  2016-08-01       Impact factor: 3.633

Review 2.  Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas.

Authors:  Georgia Ntali; John A Wass
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

3.  A prospective study of nonfunctioning pituitary adenomas: presentation, management, and clinical outcome.

Authors:  Lukui Chen; William L White; Robert F Spetzler; Bainan Xu
Journal:  J Neurooncol       Date:  2010-08-21       Impact factor: 4.130

4.  Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma.

Authors:  Jae Won Hong; Mi Kyung Lee; Sun Ho Kim; Eun Jig Lee
Journal:  Endocrine       Date:  2009-11-14       Impact factor: 3.633

5.  Dopamine agonist therapy induces significant recovery of HPA axis function in prolactinomas independent of tumor size: a large single center experience.

Authors:  Christine G Yedinak; Isabelle Cetas; Alp Ozpinar; Shirley McCartney; Aclan Dogan; Maria Fleseriu
Journal:  Endocrine       Date:  2016-07-26       Impact factor: 3.633

Review 6.  Transcranial surgery for pituitary adenomas.

Authors:  Michael Buchfelder; Juergen Kreutzer
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

7.  Hypopituitarism patterns and prevalence among men with macroprolactinomas.

Authors:  Amit Tirosh; Carlos Benbassat; Avner Lifshitz; Ilan Shimon
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

8.  Status and clinical and radiological predictive factors of presurgical anterior pituitary function in pituitary adenomas. Study of 232 patients.

Authors:  Marta Araujo-Castro; Eider Pascual-Corrales; Alberto Acitores Cancela; Sara García Duque; Luis Ley Urzaiz; Víctor Rodríguez Berrocal
Journal:  Endocrine       Date:  2020-08-12       Impact factor: 3.633

9.  Early hormonal recovery following endoscopic transsphenoidal surgery for silent non-functioning pituitary adenomas with hormone dysfunction.

Authors:  Min Ho Lee; Kyu Yeon Hur; Sang Duk Hong; Ho Jun Seol; Jung Won Choi; Jung- Il Lee; Do-Hyun Nam; Doo-Sik Kong
Journal:  J Neurooncol       Date:  2021-05-17       Impact factor: 4.130

10.  Telomerase expression in clinically non-functioning pituitary adenomas.

Authors:  Liana Lumi Ogino; Elisa Baranski Lamback; Alexandro Guterres; Carlos Henrique de Azeredo Lima; Daniel Gomes Henriques; Monique Alvares Barbosa; Débora Aparecida Silva; Aline Helen da Silva Camacho; Leila Chimelli; Leandro Kasuki; Mônica R Gadelha
Journal:  Endocrine       Date:  2020-10-22       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.